









Markets
/
Stocks
/
nasdaq-nnvc
/

NanoViricides Inc

NNVC

1.470USD

+0.050+3.52%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

23.63MMarket Cap

LossP/E TTM



NanoViricides Inc

1.470

+0.050+3.52%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

239 / 506

Overall Ranking

387 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

Fairly Valued

The company’s latest PE is -2.12, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.84M shares, decreasing 16.78% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.42.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.52, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.52

Change



Financials

2.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.05, which is -12.70% below the recent high of -1.79 and -8.45% above the recent low of -2.22.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 239/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.88, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.52 and the support level at 1.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

1.68

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.014

Neutral

RSI(14)

51.648

Neutral

STOCH(KDJ)(9,3,3)

64.969

Buy

ATR(14)

0.056

Low Volatility

CCI(14)

83.045

Neutral

Williams %R

20.000

Buy

TRIX(12,20)

-0.174

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.446

Buy

MA10

1.444

Buy

MA20

1.436

Buy

MA50

1.522

Sell

MA100

1.473

Sell

MA200

1.388

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

510.42K

Theracour Pharma, Inc.

470.96K

BlackRock Institutional Trust Company, N.A.

158.75K

Geode Capital Management, L.L.C.

154.59K

+7.87%

Renaissance Technologies LLC

Star Investors

105.80K

-27.39%

Virtu Americas LLC

27.75K

-56.40%

Bridgeway Capital Management, LLC

44.04K

State Street Global Advisors (US)

41.91K

City National Rochdale, LLC

30.54K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.57, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.